Myasthenia Gravis Treatment Market

Mar 2021| MRS125A| Market Research Studies

Report Highlights

The scope of this report covers the different types of Myasthenia Gravis Treatment along with emerging product launches for the treatment of Myasthenia Gravis Treatment. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each treatment, medication, end-user, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional Myasthenia Gravis Treatment markets; it explains the major market drivers of the Global Myasthenia Gravis Treatment industry, current trends within the industry, major applications, and the regional dynamics of the Global Myasthenia Gravis Treatment Market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the Global Myasthenia Gravis Treatment Market. Recent mergers and acquisitions, new product development is also catered in this report.

Report Includes

  • 40 tables and 48 figures
  • An up-to-date analysis of the Global Myasthenia Gravis Treatment Market.
  • Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
  • Estimation of market size and revenue forecast for Global Myasthenia Gravis Treatment Market, and corresponding market share analysis by treatment, medication, end-user, and region.
  • Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Myasthenia Gravis Treatment, identification of the companies that are best positioned to meet this demand.
  • In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
  • Identification of promising new drugs, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
  • Impact of COVID-19 on the Myasthenia Gravis Treatment Market as compared to overall global economy.
  • Insight into the growth development strategies of major Myasthenia Gravis Treatment manufacturers and their key competitive landscape
  • Descriptive company profiles of the leading market participants, Alexion Pharmaceuticals Inc., Argenx SE, Astellas Pharma Inc., CuraVac, Inc., Grifols SA, UCB Pharma S.A., Immunovant Inc., Mitsubishi Tanabe Pharma Corporation, and others.

Summary

Myasthenia Gravis, a rare neuromuscular autoimmune disease causes weakness of the skeletal muscle. Mostly affected body parts are eye, face, and throat muscles. This usually happens when there has been a disruption in the communication between muscles and the nerve cells. In myasthenia gravis, the antibodies bind with the proteins responsible for the nerve signal transmission which blocks the transmission. In some cases, the antibodies bind with acetylcholine receptor while in other cases, the antibodies attack another protein named muscle-specific kinase. There is no permanent cure for this disease, but medications and surgeries are performed to reduce the number of symptoms of the disease. Some of the common medications used during the process are cholinesterase inhibitors, corticosteroids, Immunosuppressants, plasmapheresis, intravenous immunoglobulin, and monoclonal antibody.

National Organization for Rare Disorders (NORD) an American non-profit organization states that around 14-40 per 100,000 individuals suffer from this disease. This disease occurs mostly in females than males. In case of males, the symptoms are mainly visible after the age of 50 years while in case of females, the symptoms could be visible during their 20s or 30s.

The Global Myasthenia Gravis Treatment Market was valued at $1.57 billion in 2020 and is expected to witness a steady growth at a CAGR of 7.45%.

  • Table 1 : Global Myasthenia Gravis Treatment Market, Through 2026
  • Table 2 : Global Myasthenia Gravis Treatment Market, by Treatment, Through 2026
  • Table 3 : Global Myasthenia Gravis Treatment Market, by Medication, Through 2026
  • Table 4 : Global Myasthenia Gravis Treatment Market, by End-User, Through 2026
  • Table 5 : Global Myasthenia Gravis Treatment Market, by Region, Through 2026
  • Table 6 : North America Myasthenia Gravis Treatment Market, by Treatment, Through 2026
  • Table 7 : North America Myasthenia Gravis Treatment Market, by Medication, Through 2026
  • Table 8 : North America Myasthenia Gravis Treatment Market, by End-User, Through 2026
  • Table 9 : North America Myasthenia Gravis Treatment Market, by Country, Through 2026
  • Table 10 : Europe Myasthenia Gravis Treatment Market, by Treatment, Through 2026
  • Table 11 : Europe Myasthenia Gravis Treatment Market, by Medication, Through 2026
  • Table 12 : Europe Myasthenia Gravis Treatment Market, by End-User, Through 2026
  • Table 13 : Europe Myasthenia Gravis Treatment Market, by Country, Through 2026
  • Table 14 : Asia-Pacific Myasthenia Gravis Treatment Market, by Treatment, Through 2026
  • Table 15 : Asia-Pacific Myasthenia Gravis Treatment Market, by Medication, Through 2026
  • Table 16 : Asia-Pacific Myasthenia Gravis Treatment Market, by End-User, Through 2026
  • Table 17 : Asia-Pacific Myasthenia Gravis Treatment Market, by Country, Through 2026
  • Table 18 : South America Myasthenia Gravis Treatment Market, by Treatment, Through 2026
  • Table 19 : South America Myasthenia Gravis Treatment Market, by Medication, Through 2026
  • Table 20 : South America Myasthenia Gravis Treatment Market, by End-User, Through 2026
  • Table 21 : South America Myasthenia Gravis Treatment Market, by Country, Through 2026
  • Table 22 : Middle East & Africa Myasthenia Gravis Treatment Market, by Treatment, Through 2026
  • Table 23 : Middle East & Africa Myasthenia Gravis Treatment Market, by Medication, Through 2026
  • Table 24 : Middle East & Africa Myasthenia Gravis Treatment Market, by End-User, Through 2026
  • Table 25 : Middle East & Africa Myasthenia Gravis Treatment Market, by Country, Through 2026
  • Table 26 : Alexion Pharmaceuticals Inc.: Financial Performance, Through 2020
  • Table 27 : Argenx SE: Financial Performance, Through 2020
  • Table 28 : Astellas Pharma Inc.: Financial Performance, Through 2020
  • Table 29 : CuraVac, Inc.: Financial Performance, Through 2020
  • Table 30 : Grifols SA: Financial Performance, Through 2020
  • Table 31 : UCB Pharma S.A.: Financial Performance, Through 2020
  • Table 32 : Immunovant Inc.: Financial Performance, Through 2020
  • Table 33 : Mitsubishi Tanabe Pharma Corporation: Financial Performance, Through 2020
  • Table 34 : Novartis International AG: Financial Performance, Through 2020
  • Table 35 : Bausch Health Companies Inc.: Financial Performance, Through 2020
  • Table 36 : Avadel Pharmaceuticals plc.: Financial Performance, Through 2020
  • Table 37 : AbbVie Inc.: Financial Performance, Through 2020
  • Table 38 : F. Hoffmann-La Roche AG: Financial Performance, Through 2020
  • Table 39 : Catalyst Pharmaceuticals, Inc.: Financial Performance, Through 2020
  • Table 40 : Cytokinetics, Inc.: Financial Performance, Through 2020
  • Figure 1 : Global Myasthenia Gravis Treatment Market
  • Figure 2 : Global Myasthenia Gravis Treatment Market, by Value, 2019-2026
  • Figure 3 : Global Myasthenia Gravis Treatment Market, by Value, by Treatment, 2019-2026
  • Figure 4 : Global Myasthenia Gravis Treatment Market, by Value, by Medication, 2019-2026
  • Figure 5 : Global Myasthenia Gravis Treatment Market, by Value, by End-User, 2019-2026
  • Figure 6 : Global Myasthenia Gravis Treatment Market, by Value, by Region, 2020
  • Figure 7 : Global Myasthenia Gravis Treatment Market, by Value, by Company, 2020
  • Figure 8 : Global Myasthenia Gravis Treatment Market, Product Map, 2020
  • Figure 9 : North America Myasthenia Gravis Treatment Market, by Value, 2019-2026
  • Figure 10 : North America Myasthenia Gravis Treatment Market, by Value, by Treatment, 2019-2026
  • Figure 11 : North America Myasthenia Gravis Treatment Market, by Value, by Medication, 2019-2026
  • Figure 12 : North America Myasthenia Gravis Treatment Market, by Value, by End-User, 2019-2026
  • Figure 13 : North America Myasthenia Gravis Treatment Market, by Value, by Country, 2020
  • Figure 14 : Europe Myasthenia Gravis Treatment Market, by Value, 2019-2026
  • Figure 15 : Europe Myasthenia Gravis Treatment Market, by Value, by Treatment, 2019-2026
  • Figure 16 : Europe Myasthenia Gravis Treatment Market, by Value, by Medication, 2019-2026
  • Figure 17 : Europe Myasthenia Gravis Treatment Market, by Value, by End-User, 2019-2026
  • Figure 18 : Europe Myasthenia Gravis Treatment Market, by Value, by Country, 2020
  • Figure 19 : Asia-Pacific Myasthenia Gravis Treatment Market, by Value, 2019-2026
  • Figure 20 : Asia-Pacific Myasthenia Gravis Treatment Market, by Value, by Treatment, 2019-2026
  • Figure 21 : Asia-Pacific Myasthenia Gravis Treatment Market, by Value, by Medication, 2019-2026
  • Figure 22 : Asia-Pacific Myasthenia Gravis Treatment Market, by Value, by End-User, 2019-2026
  • Figure 23 : Asia-Pacific Myasthenia Gravis Treatment Market, by Value, by Country, 2020
  • Figure 24 : South America Myasthenia Gravis Treatment Market, by Value, 2019-2026
  • Figure 25 : South America Myasthenia Gravis Treatment Market, by Value, by Treatment, 2019-2026
  • Figure 26 : South America Myasthenia Gravis Treatment Market, by Value, by Medication, 2019-2026
  • Figure 27 : South America Myasthenia Gravis Treatment Market, by Value, by End-User, 2019-2026
  • Figure 28 : South America Myasthenia Gravis Treatment Market, by Value, by Country, 2020
  • Figure 29 : Middle East & Africa Myasthenia Gravis Treatment Market, by Value, 2019-2026
  • Figure 30 : Middle East & Africa Myasthenia Gravis Treatment Market, by Value, by Treatment, 2019-2026
  • Figure 31 : Middle East & Africa Myasthenia Gravis Treatment Market, by Value, by Medication, 2019-2026
  • Figure 32 : Middle East & Africa Myasthenia Gravis Treatment Market, by Value, by End-User, 2019-2026
  • Figure 33 : Middle East & Africa Myasthenia Gravis Treatment Market, by Value, by Country, 2020
  • Figure 34 : Alexion Pharmaceuticals Inc.: Revenue Share, 2020
  • Figure 35 : Argenx SE: Revenue Share, 2020
  • Figure 36 : Astellas Pharma Inc.: Revenue Share, 2020
  • Figure 37 : CuraVac, Inc.: Revenue Share, 2020
  • Figure 38 : Grifols SA: Revenue Share, 2020
  • Figure 39 : UCB Pharma S.A.: Revenue Share, 2020
  • Figure 40 : Immunovant Inc.: Revenue Share, 2020
  • Figure 41 : Mitsubishi Tanabe Pharma Corporation: Revenue Share, 2020
  • Figure 42 : Novartis International AG: Revenue Share, 2020: Revenue Share, 2020
  • Figure 43 : Bausch Health Companies Inc.: Revenue Share, 2020
  • Figure 44 : Avadel Pharmaceuticals plc.: Revenue Share, 2020
  • Figure 45 : AbbVie Inc.: Revenue Share, 2020
  • Figure 46 : F. Hoffmann-La Roche AG: Revenue Share, 2020
  • Figure 47 : Catalyst Pharmaceuticals, Inc.: Revenue Share, 2020
  • Figure 48 : Cytokinetics, Inc.: Revenue Share, 2020

Market Research Studies is a North Carolina based, premier market research company. MRS brings over 50 years of market research publishing experience. Our reports cover a variety of industries such as Healthcare, Chemicals, Materials & Manufacturing, Research & Diagnostics, Environment & Sustainability, among others. Each year MRS releases hundreds of reports covering various topics. These reports are prepared by our in-house of team of Industry expert analysts. We strive to provide in-depth market analysis with accurate data to help our customers make informed decisions.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report